AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01977287 — intervention group
Intervention type: DEVICE
Intervention: Ankle Foot Orthosis
Study NCT02705703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
Study NCT03704740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
Study NCT03704740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Description: Influenza virus surface antigens of three strains (trivalent)
Study NCT02624596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
Study NCT02624596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
Study NCT02226900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Revascularization
Description: Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
Study NCT02226900 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Coronary Artery Bypass Surgery
Description: On pump coronary artery by-pass surgery
Study NCT01936610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: role play
Description: In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
Study NCT02697045 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole 400mg LAI
Description: Aripiprazole 400mg, IM, Once a month
Study NCT01800370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Description: Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
Study NCT01800370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
Study NCT01800370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.
Study NCT01305018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7 g of leucine + 7 g of alanine per day during 9 days
Study NCT01305018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 g of alanine per day during 9 days
Study NCT04058080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bikram Yoga
Description: Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
Study NCT04058080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
Study NCT05729529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipoid acid gel
Description: Topic lipoid acid gel used with topic oral gel used on tongue
Study NCT05729529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral gel used on tongue
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 1 mg, once on Day 1 only, 2 days
Study NCT01135446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
Study NCT01409278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration and saline infusion.
Description: 50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
Study NCT01800370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
Study NCT01800370 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draws
Description: Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
Study NCT01800370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting procedure
Description: Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
Study NCT01936610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lecture
Description: Describe advantages and disadvantages in one 90-min session
Study NCT01800370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fasting procedure
Description: Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
Study NCT02103075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
Study NCT02907372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychologic evaluation
Study NCT02907372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oncogeriatric evaluation
Study NCT02114684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: \[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
Study NCT01409278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration and infusion.
Description: 50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
Study NCT01409278 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
Study NCT03945422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuTite/FaceTite
Description: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
Study NCT03287310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
Study NCT04728256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter therapy+Music listening+Keeping diary
Description: Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings.
Study NCT02883556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
Study NCT04192331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel regimen1
Description: nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.
Study NCT04192331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel regimen2
Description: nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
Study NCT01495988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Study NCT04685811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
Description: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
Study NCT01680913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
Study NCT01495988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Study NCT03780595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata
Description: Passiflora pills administration up to 6 pills per day
Study NCT03780595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control pills administration up to 6 pills per day
Study NCT05107245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1test1
Description: Loss of bacterial diversity diagnosis
Study NCT01495988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
Study NCT01495988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobimetinib
Description: Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
Study NCT01495988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
Study NCT05766579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic-compressive stockings
Description: Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
Study NCT03747445 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: laparoscopic surgical procedure
Study NCT03234335 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
Study NCT03287310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
Study NCT03287310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/albuterol
Description: Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
Study NCT03287310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/albuterol
Description: Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
Study NCT01680913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation of Tuffier's line
Description: Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
Study NCT01680913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthetic
Description: Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
Study NCT01680913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthetic
Description: Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
Study NCT02761538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVIITAM
Description: The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~.
Study NCT02757014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
Study NCT02990962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
Study NCT02990962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1cc 2% Xylocaine+4cc Triamcinolone (40mg)
Description: Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
Study NCT00191100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00191100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00191100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT00678717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic Evaluation
Description: Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
Study NCT00678717 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autonomic Evaluation
Description: Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
Study NCT00191100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy, 30-35 Gy over 1 week
Study NCT00191100 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy, 30-35 Gy over 1 week
Study NCT00191100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiation
Description: Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Study NCT00191100 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic radiation
Description: Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Study NCT02811159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone acetate
Description: Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
Study NCT01981057 — intervention group
Intervention type: OTHER
Intervention: Numeta
Description: parenteral receipt prescribed with Numeta
Study NCT03395210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: BTK inhibitor
Study NCT01854294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM604
Description: GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Study NCT01981057 — intervention group
Intervention type: OTHER
Intervention: Individual
Description: parenteral receipt prescribed individually
Study NCT01854294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).